Johnson & Johnson also gains an exclusive option to acquire Sail Biosciences for $2.85 billion. The deal puts J&J in the mix of pharmaceutical companies developing next-generation cell therapies for applications in autoimmune diseases.
The post J&J Joins Immune Reset Race, Paying $785M to Partner on Sail Bio Cell Therapy appeared first on MedCity News.
